美国

证券和交易所委员会

华盛顿特区20549

表格 8-K

现时报告
根据第13或15(d)条款
《1934年证券交易法》

2024年8月29日

报告日期（最早报告事件日期）

agba group holding limited

（在其章程中指定的注册名称）

注册人的电话号码，包括区号：＋852 3601 8000

无数据

（如果自上次报告以来地址或名称有变更，请填写上次地址或名称）

如此收件人希望，检查以下适用的选框，指的是提交8-K表格的同时满足注册人根据以下任一规定的提交及报告责任:

根据法案第12(b)条注册的证券：

请勾选相应的选项，说明报告的申报者是否符合《1933年证券法规则405条》（17 CFR §230.405）或《1934年证券交易法规则120亿.2》（17 CFR §2401.2亿.2）中定义的新兴成长性公司的要求。

新兴成长公司 ☒

如果是新兴增长公司，请勾选以下项目：是否选择不使用根据证券交易法第13(a)条提供的任何新或修订的财务会计准则符合延长的过渡期。☐

项5.02. 董事离任或特定高管离职；董事选举；特定高管任命；特定高管薪酬安排。

（b）合并、合并或其他业务组合（称为“业务组合”）的结束，除了一种业务组合以后业务组合之前股东拥有普通股或普通股的相同比例所有权的业务组合之外。

(c) 将除非关联公司以外的所有或几乎全部公司资产出售或处置给任何实体的协议的结束；

(d) 股东批准的公司完全清算计划，不包括公司合并为任何子公司或清算后，原公司股东在清算前后持有的普通股或普通股的比例基本相同；

（e）在任何连续二十四（24）个月中，现任董事不能构成董事会或任何继任公司董事会的多数; 但是，获得多数现任董事选举入董事会或获得现任董事通过提名的董事，应被视为本段（e）的现任董事。但出于此目的，不包括因存在候选董事选举或其他实际或威胁性的代理人或同意函指示由董事会以外的个人、实体或“集团”（含但不限于基于本定义的段（a）、（b）、（c）或（d）进行的行为）而被选任所致的个人。

1.董事选举

2.8“代码”指1986年修订后的《国内税收法典》（Internal Revenue Code of 1986），以及后续的任何修改。计划中对代码的任何部分的引用应视为包括该部分下的任何法规或其他解释指导以及对该部分、法规或指导的修改或后续规定。

2.38 “限制”指根据受限股奖励计划（Plan）根据受限股奖励协议（Restricted Stock Agreement）授予员工、董事或顾问的股份所适用的没收、转让和/或其他限制。

2.39 “规则160亿.3”指美国证券交易委员会根据《交易所法》制定的规则160亿.3，该规则可能会不时修订，并能够完成相同或实质相似的功能的任何继任规则、法规或法规。

项目9.01：财务报表和展览。

(d) 展示材料。

签名

根据1934年证券交易法的要求，申报人已授权下面签署此报告。

Loss after tax for FY2024 was US$8800万, a 7% increase compared to US$8190万 for FY2023. The net loss attributable to ordinary shareholders was 8.91 US cents per share for FY2024, compared with 10.53 US cents per share for FY2023. Conference Call There will be a webcast today, beginning at 8.30am AESt (Thursday, August 29); 6.30pm EDt (Wednesday, August 28). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late- stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. Jagasia m et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749 2. Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43. 3. Wittenberg RE, Gauvreau k, Leighton J, Moleon-Shea m, Borow Km, Marx GR, Emani Sm, Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome, JTCVS Open Volume 16, Dec 2023, doi: https://doi.org/10.1016/j.xjon.2023.09.031 4. Symons JD, Deeter L, Deeter N, et al. Effect of continuous-flow left ventricular assist device support on coronary artery endothelial function in ischemic and nonischemic cardiomyopathy. Cir Heart Fail 2019; 12:e006085. DOI: 10.1161/CIRCHEARTFAILURE.119.006085. 5. Using Reserve Bank of Australia (RBA) published exchange rate from June 30, 2024 of 1A$:0.6624US$. 6. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. 7. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:140.01 Yen for the twelve months ended June 30, 2023 to 1USD:151.75 Yen for the twelve months ended June 30, 2024. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our

3